Accumulated Pre-Switch Resistance to More Recently Introduced One-Pill-Once-a-Day Antiretroviral Regimens Impacts HIV-1 Virologic Outcome

Antiretroviral therapy (ART) adherence is a major challenge to sustained virologic suppression [1]. Atripla (tenofovir disoproxil fumarate (TDF), emtricitabine, efavirenz), the first one-pill-once-a-day (OPOD) regimen, has appealed to providers and patients since 2006, with improved ease of use and virologic suppression compared to multi-pill regimens [2 –8]. Complera (rilpivirine, TDF, emtricitabine) and Stribild (elvitegravir, cobicistat, TDF, emtricitabine) became additional OPOD options in 2011 and 2012 [9,10], addressing Atripla’s limitations, mostly side-effects, teratogenicity concerns, and low genetic resistance barrier [11].
Source: Journal of Clinical Virology - Category: Virology Authors: Source Type: research